Further reductions in the prices of generic versions of key second-line antiretroviral drugs were announced yesterday, thanks to an agreement negotiated by the international drug purchase fund UNITAID and the Clinton HIV/AIDS Initiative with Indian and Chinese generic drug manufacturers. Under the deal the cost of tenofovir, 3TC (lamivudine) and lopinavir/ritonavir will fall by almost a fifth compared to prices a year ago. Six new, easy to take child-friendly antiretroviral formulations will also be made available by the deal, and a paediatric fixed-dose combination of AZT, 3TC and nevirapine will cost no more than $66 per year. [refers to Matrix Laboratories, Aurobindo Pharma, Cipla]